CEO Mitchell Steiner highlighted Veru's transition to a pure-play late clinical stage biopharmaceutical company focused on cardiometabolic and inflammatory diseases, following the divestiture of the ...
-- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter— --Company to host conference call and webcast ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results